Genexine Seeks China Entry Through Multi-Biologic Tasly Tie-Up
This article was originally published in PharmAsia News
South Korean biotech firm Genexine is broadening its presence in Asia. Following an agreement earlier this month with Kalbe Farma to set up a joint venture in Indonesia, it has now signed a licensing out deal for protein therapies with a subsidiary of China’s Tasly Pharmaceutical.
You may also be interested in...
Genexine has reached a critical point in developing its immuno-oncology pipeline, firming up a $548m-plus licensing out pact for an asset with the Shanghai-based I-Mab Biopharma. The South Korean firm expects the deal to serve as a yardstick of ‘value determination’ in its future global transactions.
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.